Literature DB >> 11273885

Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma.

T Rickman1, R Garmany, T Doherty, D Benson, M D Okusa.   

Abstract

Ectopic adrenocorticotropic hormone (ACTH) and/or corticotropin-releasing hormone (CRH) are associated with a growing list of tumors. We report a 69-year-old white man with a history of high-grade prostate carcinoma and widely metastatic adenocarcinoma who presented with metabolic alkalosis, hypokalemia, and hypertension secondary to ectopic ACTH and CRH secretion. Laboratory values were consistent with hypokalemia and metabolic alkalosis. Markedly elevated serum cortisol (135 microg/dL), ACTH (1,387 pg/dL), CRH (69 pg/dL), and urine free cortisol (16,276 microg/24 h) levels were found. Chest computed tomographic (CT) scan showed small noncalcified parenchymal densities; however, bronchoscopy and bronchoalveolar lavage washings were unremarkable for a neoplastic process. Abdominal CT scan and magnetic resonance imaging showed multiple small liver lesions and multiple thoracic and lumbar intensities consistent with diffuse metastatic disease. Histological analysis of a biopsy specimen from the thoracic spine showed an undifferentiated adenocarcinoma consistent with a prostate primary tumor. The severe metabolic alkalosis secondary to glucocorticoid-induced excessive mineralocorticoid activity was treated with potassium supplements, spironolactone, and ketoconazole. In this case report, we describe an unusual tumor associated with ectopic ACTH and CRH production and the pharmacodynamic relationship of plasma cortisol levels and urinary cortisol excretion with ketoconazole treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11273885     DOI: 10.1016/s0272-6386(01)80134-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

Review 1.  Ectopic cushing's syndrome due to corticotropin releasing hormone.

Authors:  Manouchehr Nakhjavani; Alireza Amirbaigloo; Soghra Rabizadeh; Fabio Rotondo; Kalman Kovacs; Ali A Ghazi
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 2.  Paraneoplastic syndromes in prostate cancer.

Authors:  Matthew K Hong; Jennifer Kong; Benjamin Namdarian; Anthony Longano; Jeremy Grummet; Christopher M Hovens; Anthony J Costello; Niall M Corcoran
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

3.  Cushing's syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma.

Authors:  R A Alwani; S J C M M Neggers; M van der Klift; M G A Baggen; G J L H van Leenders; M O van Aken; A J van der Lely; W W de Herder; R A Feelders
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 4.  En Bloc Resection of Solitary Functional Secreting Spinal Metastasis.

Authors:  C Rory Goodwin; Michelle J Clarke; Ziya L Gokaslan; Charles Fisher; Ilya Laufer; Michael H Weber; Daniel M Sciubba
Journal:  Global Spine J       Date:  2015-07-16

Review 5.  Severe Cushing's syndrome due to small cell prostate carcinoma: a case and review of literature.

Authors:  M S Elston; V B Crawford; M Swarbrick; M S Dray; M Head; J V Conaglen
Journal:  Endocr Connect       Date:  2017-06-05       Impact factor: 3.335

6.  ECTOPIC ADRENOCORTICOTROPIC HORMONE SYNDROME DUE TO METASTATIC PROSTATE CANCER WITH NEUROENDOCRINE DIFFERENTIATION.

Authors:  Malini Soundarrajan; Henry Zelada; Jean Victoria Fischer; Peter Kopp
Journal:  AACE Clin Case Rep       Date:  2019-04-25

7.  Undetected hypoparathyroidism: An unusual cause of perioperative morbidity.

Authors:  Ashish Chakravarty; Saurabh Anand; Harsh Sapra; Yatin Mehta
Journal:  Indian J Anaesth       Date:  2014-07

8.  Dual Paraneoplastic Endocrine Syndromes Heralding Onset of Extrapulmonary Small Cell Carcinoma: A Case Report and Narrative Review.

Authors:  Jill B Feffer; Natalia M Branis; Jeanine B Albu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-18       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.